Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024 at 10:00 AM ET. To register, click here.

The event will feature presentations by company management and key opinion leaders related to the Company’s lead program, atrioventricular interval modulation (AVIM) therapy, including:

• David Kandzari, M.D., FACC, FSCAI, Chief, Piedmont Heart Institute and Cardiovascular Services, Chief Scientific Officer, Piedmont Healthcare, Director, Interventional Cardiology, Piedmont Heart Institute, and Co-principal investigator for the BACKBEAT global pivotal study
• Vivek Reddy, M.D., Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, Director of Electrophysiology at Mount Sinai Health System, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Clinical Steering Committee Advisor for the BACKBEAT global pivotal study

The R&D day program will focus on a review of:

• High unmet need and current treatment landscape for pacemaker-indicated patients with uncontrolled hypertension;
• AVIM therapy mechanism of action and supporting clinical and non-clinical mechanistic data;
• Existing body of clinical evidence from the MODERATO I and II studies;
• Design of the BACKBEAT global pivotal study.

A live question and answer session will follow formal presentations.

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.